glp-1 ibd The alleviating effect and mechanism of on ulcerative colitis OBESITY AND IBD by @EdwardLoftus2

BPC-157 is not FDA-approved for any therapeutic indication as of 2026

Is the use of peptides considered doping

Patients who are overweight or dealing with PCOS (polycystic ovarian syndrome) probably also have an insulin insensitivity

B12 does not directly enhance the weight loss effects of tirzepatide, but it may improve the overall experience by mitigating fatigue, a common side effect

Many patients lost approximately 10% to 15% of total body weight over time when combined with nutrition and exercise improvements

Clinical trials show both semaglutide and tirzepatide have favorable safety profiles when used as directed, with nausea and gastrointestinal effects being most common, occurring in roughly 25-40% of users